AI Engines For more Details: Perplexity Kagi Labs You
Glycemic Control: L-sorbose has been studied for its potential benefits in improving glycemic control and insulin sensitivity. Unlike glucose, L-sorbose is poorly metabolized by the body and does not significantly raise blood sugar levels. It has been shown to stimulate the production of glucagon-like peptide-1 (GLP-1), a hormone that helps regulate blood glucose levels and insulin secretion. L-sorbose supplementation may help reduce postprandial blood glucose spikes and improve glucose tolerance in individuals with diabetes or impaired glucose metabolism.
Weight Management: L-sorbose may have potential benefits for weight management and obesity prevention. Studies in animals have shown that L-sorbose supplementation can reduce food intake, inhibit the absorption of dietary fat, and promote weight loss. L-sorbose may act as a satiety signal, suppressing appetite and reducing calorie intake. It may also modulate lipid metabolism and adipose tissue function, leading to decreased fat accumulation and improved body composition.
Liver Health: L-sorbose has been investigated for its potential hepatoprotective effects and its ability to mitigate liver damage caused by various insults, including alcohol consumption, drug toxicity, and metabolic disorders. L-sorbose supplementation has been shown to enhance liver regeneration, reduce inflammation, and improve liver function markers in animal studies. It may help protect against liver fibrosis, non-alcoholic fatty liver disease (NAFLD), and other liver-related conditions.
Antioxidant Properties: L-sorbose exhibits antioxidant properties and may help scavenge free radicals and reduce oxidative stress in the body. Oxidative stress plays a role in the pathogenesis of various chronic diseases, including cardiovascular disease, neurodegenerative disorders, and cancer. L-sorbose supplementation may help protect cells and tissues from oxidative damage and support overall health and longevity.
Gut Health: L-sorbose may have potential benefits for gut health and digestive function. It is fermented by gut bacteria in the colon, leading to the production of short-chain fatty acids (SCFAs) such as butyrate, which serve as an energy source for colonocytes and help maintain gut barrier function. L-sorbose fermentation may promote the growth of beneficial gut bacteria and modulate the gut microbiota composition, leading to improved gastrointestinal health and immune function.
Anti-inflammatory Effects: L-sorbose may have anti-inflammatory effects and may help modulate immune responses and inflammatory pathways in the body. Chronic inflammation is implicated in the pathogenesis of many diseases, including autoimmune disorders, metabolic syndrome, and neurodegenerative conditions. L-sorbose supplementation may help reduce systemic inflammation and attenuate inflammatory cytokine production, leading to improved health outcomes.
| Rank | Probiotic | Impact |
|---|---|---|
| species | Lactobacillus acidophilus | Increases |
| species | Lactobacillus crispatus | Increases |
| species | Lactobacillus gasseri | Increases |
| species | Lactobacillus helveticus | Increases |
| species | Lactobacillus jensenii | Increases |
| species | Lactobacillus johnsonii | Increases |
| species | Lactobacillus kefiranofaciens | Increases |
| species | Streptococcus thermophilus | Increases |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Acne | 1.5 | 0.3 | 4 |
| ADHD | 2.1 | 2 | 0.05 |
| Age-Related Macular Degeneration and Glaucoma | 0.6 | 0.6 | 0 |
| Allergic Rhinitis (Hay Fever) | 2.2 | 2.2 | 0 |
| Allergies | 1.6 | 2.3 | -0.44 |
| Allergy to milk products | 0.7 | 0.9 | -0.29 |
| Alopecia (Hair Loss) | 2 | -2 | |
| Alzheimer's disease | 3.8 | 1.8 | 1.11 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 0.6 | 3.4 | -4.67 |
| Ankylosing spondylitis | 1.5 | 3 | -1 |
| Anorexia Nervosa | 3.2 | 2.1 | 0.52 |
| Antiphospholipid syndrome (APS) | 1.1 | -1.1 | |
| Asthma | 2.8 | 4.2 | -0.5 |
| Atherosclerosis | 0.3 | 1 | -2.33 |
| Atrial fibrillation | 1.2 | 3.4 | -1.83 |
| Autism | 4.8 | 5.5 | -0.15 |
| Autoimmune Disease | 1.5 | 0.7 | 1.14 |
| Barrett esophagus cancer | 1.3 | 1.3 | |
| benign prostatic hyperplasia | 0.3 | 0.3 | |
| Biofilm | 1.7 | -1.7 | |
| Bipolar Disorder | 1.2 | 0.3 | 3 |
| Brain Trauma | 0.9 | 1.5 | -0.67 |
| Breast Cancer | 0.4 | -0.4 | |
| Cancer (General) | 0.9 | 0.9 | |
| Carcinoma | 1 | 1.9 | -0.9 |
| Celiac Disease | 3.7 | 2.1 | 0.76 |
| Cerebral Palsy | 1.3 | 0.6 | 1.17 |
| Chronic Fatigue Syndrome | 3.4 | 2.1 | 0.62 |
| Chronic Kidney Disease | 2.4 | 0.3 | 7 |
| Chronic Lyme | 0.3 | 0.3 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 1.9 | 4.2 | -1.21 |
| Chronic Urticaria (Hives) | 0.3 | 0.6 | -1 |
| Coagulation / Micro clot triggering bacteria | 2.9 | 0.8 | 2.62 |
| Cognitive Function | 1.9 | 2 | -0.05 |
| Colorectal Cancer | 1.8 | 3.8 | -1.11 |
| Constipation | 0.7 | 0.7 | 0 |
| Coronary artery disease | 3.1 | 1.8 | 0.72 |
| COVID-19 | 5.5 | 5.5 | 0 |
| Crohn's Disease | 4.5 | 4.9 | -0.09 |
| cystic fibrosis | 0.7 | 0.7 | |
| d-lactic acidosis (one form of brain fog) | 1.2 | -1.2 | |
| deep vein thrombosis | 2.2 | 1.2 | 0.83 |
| Denture Wearers Oral Shifts | 1.2 | 1.8 | -0.5 |
| Depression | 5.7 | 6.6 | -0.16 |
| Dermatomyositis | 1 | -1 | |
| Eczema | 1.2 | 0.6 | 1 |
| Endometriosis | 1.9 | 2.3 | -0.21 |
| Eosinophilic Esophagitis | 1.5 | 1.5 | |
| Epilepsy | 1.6 | 3.3 | -1.06 |
| erectile dysfunction | 1.6 | -1.6 | |
| Fibromyalgia | 1.2 | 2.2 | -0.83 |
| Functional constipation / chronic idiopathic constipation | 2 | 2.1 | -0.05 |
| gallstone disease (gsd) | 0.9 | 1.5 | -0.67 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 2.7 | 0.8 | 2.38 |
| Generalized anxiety disorder | 1.2 | 1.9 | -0.58 |
| Glioblastoma | 1.8 | 1.8 | |
| Gout | 0.9 | 0.6 | 0.5 |
| Graves' disease | 4.2 | 0.9 | 3.67 |
| Gulf War Syndrome | 0.6 | 1.6 | -1.67 |
| Halitosis | 1.2 | 1.5 | -0.25 |
| Hashimoto's thyroiditis | 1.4 | 2.8 | -1 |
| Heart Failure | 2.6 | 2.2 | 0.18 |
| hemorrhagic stroke | 0.3 | 1.2 | -3 |
| Hidradenitis Suppurativa | 0.6 | 1.4 | -1.33 |
| High Histamine/low DAO | 0.3 | 1 | -2.33 |
| hypercholesterolemia (High Cholesterol) | 0.3 | -0.3 | |
| hyperglycemia | 1 | 1.5 | -0.5 |
| Hyperlipidemia (High Blood Fats) | 1.4 | 1.4 | |
| hypersomnia | 1 | 0 | 0 |
| hypertension (High Blood Pressure | 3.9 | 4.2 | -0.08 |
| Hypothyroidism | 2.5 | 0.3 | 7.33 |
| Hypoxia | 0.6 | 0.9 | -0.5 |
| IgA nephropathy (IgAN) | 1.8 | 1.3 | 0.38 |
| Inflammatory Bowel Disease | 5.4 | 3 | 0.8 |
| Insomnia | 1.9 | 4 | -1.11 |
| Intelligence | 1.5 | -1.5 | |
| Intracranial aneurysms | 0.9 | 0.9 | 0 |
| Irritable Bowel Syndrome | 2.8 | 4.9 | -0.75 |
| ischemic stroke | 1.7 | 1.9 | -0.12 |
| Liver Cirrhosis | 3.2 | 5.3 | -0.66 |
| Long COVID | 4.8 | 5.4 | -0.13 |
| Low bone mineral density | 1.3 | 0.5 | 1.6 |
| Lung Cancer | 1.6 | 1.6 | |
| Mast Cell Issues / mastitis | 1.2 | 0.6 | 1 |
| ME/CFS with IBS | 0.7 | -0.7 | |
| ME/CFS without IBS | 0.3 | 0.6 | -1 |
| membranous nephropathy | 0.6 | -0.6 | |
| Menopause | 1 | 0.6 | 0.67 |
| Metabolic Syndrome | 4.6 | 4.5 | 0.02 |
| Mood Disorders | 4.9 | 6.7 | -0.37 |
| multiple chemical sensitivity [MCS] | 0.4 | 2.5 | -5.25 |
| Multiple Sclerosis | 4.4 | 3 | 0.47 |
| Multiple system atrophy (MSA) | 0.4 | 0.9 | -1.25 |
| myasthenia gravis | 0.3 | 1.5 | -4 |
| neuropathic pain | 1 | 1 | |
| Neuropathy (all types) | 0.9 | 2.5 | -1.78 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.6 | 0.6 | 0 |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 3.3 | 3.8 | -0.15 |
| NonCeliac Gluten Sensitivity | 0.6 | 0.4 | 0.5 |
| Obesity | 6.2 | 4.3 | 0.44 |
| obsessive-compulsive disorder | 4.7 | 1 | 3.7 |
| Osteoarthritis | 0.6 | 2.1 | -2.5 |
| Osteoporosis | 2.6 | 2.1 | 0.24 |
| pancreatic cancer | 1.2 | 0.7 | 0.71 |
| Parkinson's Disease | 6.3 | 4.9 | 0.29 |
| Peanut Allergy | 0.6 | 0.6 | |
| Polycystic ovary syndrome | 2.9 | 3.8 | -0.31 |
| Postural orthostatic tachycardia syndrome | 0.3 | 0.3 | 0 |
| Premenstrual dysphoric disorder | 0.3 | 0.7 | -1.33 |
| primary biliary cholangitis | 1.2 | 2.1 | -0.75 |
| Primary sclerosing cholangitis | 3 | 1.5 | 1 |
| Psoriasis | 0.7 | 1.9 | -1.71 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 3.5 | 5.8 | -0.66 |
| Rosacea | 0.9 | 0.9 | |
| Schizophrenia | 3.4 | 4.9 | -0.44 |
| scoliosis | 0.9 | -0.9 | |
| sensorineural hearing loss | 0.6 | 0.2 | 2 |
| Sjögren syndrome | 1.6 | 1.4 | 0.14 |
| Sleep Apnea | 1.6 | 1.9 | -0.19 |
| Slow gastric motility / Gastroparesis | 0.6 | 0.6 | |
| Small Intestinal Bacterial Overgrowth (SIBO) | 1.8 | -1.8 | |
| Stress / posttraumatic stress disorder | 1.2 | 1.8 | -0.5 |
| Systemic Lupus Erythematosus | 2.9 | 2.5 | 0.16 |
| Tic Disorder | 0.4 | 0.6 | -0.5 |
| Tourette syndrome | 0.6 | 1 | -0.67 |
| Type 1 Diabetes | 1.6 | 3.1 | -0.94 |
| Type 2 Diabetes | 3.9 | 5.6 | -0.44 |
| Ulcerative colitis | 2.8 | 5.1 | -0.82 |
| Unhealthy Ageing | 1.6 | 2.5 | -0.56 |
| Vitiligo | 0.3 | 1.3 | -3.33 |
